|Description||L-768242, an indole derivative, has been found to be a CB2 receptor agonist and was once studied to exhibit anti-nociceptive and antihyperalgesic activities in neuropathic and inflammatory pain models.|
|Synonyms||GW-405833; (2,3-Dichloro-phenyl)-[5-methoxy-2-methyl-3-(2-morpholin-4-yl-ethyl)-indol-1-yl]-methanone; (2,3-dichlorophenyl)(5-methoxy-2-methyl-3-(2-morpholinoethyl)-1H-indol-1-yl)methanone; GW405833|
|Storage||Store in a cool and dry place and at 0 - 4 °C for short term (days to weeks) or -20 °C for long term (months to years).|
|Quality Standard||In-house standard|
L-768242, an indole derivative, has been found to be a CB2 receptor agonist and was once studied to exhibit anti-nociceptive and antihyperalgesic activities in ...
AM-1220 is a selective cannabinoid receptor CB1 agonist , with about 19x selectivity for CB1 over the related CB2 receptor originated by Sterling Winthrop. In O...
Leelamine, a diterpene molecule, has weak affinity for the human central cannabinoid (CB1) and peripheral cannabinoid (CB2) receptors. Leelamine is also a PDK(p...
BAY 38-7271, also called as KN 38-7271, is a cannabinoid receptor agonist with analgesic and neuroprotective effects. The doses of BAY 38-7271 in animals needed...
AM1248 is an adamantoylindole derivative acts as a moderately potent agonist for both the cannabinoid receptors CB1 and CB2.
BML-190 is a selective cannabinoid CB2 receptor inverse agonist with Ki of 435 nM, with 50-fold selectivity over CB1 receptor.
WIN 55212-2 mesylate
The mesylate salt form of WIN 55212-2, an aminoalkylindole derivative, is a CB receptor agonist and could be effective against some inflammatory reponse. IC50: ...
(R)-(+)-SLV 319 is a less active enantiomer of SLV 319, which is a central cannabinoid (CB1) receptor antagonist. SLV 319 has the potential to treat neuroinflam...
Otenabant HCl is a selective and high affinity antagonist of CB1 with Ki value of 0.7 nM.
Rosonabant is a CB1 receptor antagonist/inverse agonist originated by Esteve. It is an appetite suppressant for the treatment of obesity. But development of the...
Drinabant is a highly potent, selective antagonist for the CB1 receptor with Ki values of 0.16-0.44 nM.
A-836339 is a synthetic and potent cannabinoid receptor full agonist. It displays a higher affinity for the peripheral CB2 receptor with Ki value of 0.64 nM ove...
Org 27569 is an allosteric modulator of cannabinoid CB1 receptor, induces a CB1 receptor state that is characterized by enhanced agonist affinity and decreased ...
Rimonabant Hydrochloride, used as a tool to investigate CB receptor properties, it is a selective antagonist of cannabinoid CB1 receptor (Ki = 1.98 nM) and inve...
Ibipinabant is a potent and selective CB1 receptor antagonist with Ki values of 7.8 and 7,943 nM for CB1 and peripheral cannabinoid (CB2), respectively.
CB1-IN-1 is an antagonist of cannabinoid receptor type 1 (CB1R) located in the peripheral nervous system, which may be significant for pain modulation.
Otenabant, also known as CP-945,598, is a drug which acts as a potent and highly selective CB1 antagonist. It was developed by Pfizer for the treatment of obesi...
Levonantrado is a synthetic cannabinoid analog of dronabinol developed by Pfizer in the 1980s. Levonantrado is around 30x more potent than THC, and exhibits ant...
AM 2232, a synthetic cannabimimetic indole derivative, is a potent and selective agonist for the cannabinoid receptor, with Ki values of 0.28 and 1.48 nM for th...
AM251 block the inhibitory effects of endocannabinoids and synthetic cannabinoid agonists on transmitter release through an action at presynaptic cannabinoid 1 ...